

24 October 2012

## Update - Australian Microcap Investment Conference Presentation

As advised on the 16<sup>th</sup> October, Managing Director Mark Diamond presented at the 3rd Annual Australian Microcap Investment Conference on Wednesday 17<sup>th</sup> October. This presentation is now available for viewing on the Boardroom Radio website at the following link:

<http://www.brrmedia.com/event/105547>

This link will also be available on Antisense Therapeutics' website homepage - ([www.antisense.com.au](http://www.antisense.com.au)).

**Antisense Therapeutics Limited** (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc., world leaders in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with multiple sclerosis, ATL1103 a second-generation antisense drug designed to block GHr production and thereby lower blood IGF-I levels and is in clinical development as a potential treatment for growth and other GH-IGF-I disorders, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for prostate cancer.

### Contact Information:

Website: [www.antisense.com.au](http://www.antisense.com.au)

Managing Director: Mark Diamond +61 (3) 9827 8999

Investor Relations: Simon Watkin +61 (0) 413 153 272